SCHEMBL14922277

SCHEMBL14922277

Cc1cc(F)ccc1N1CCN(C)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
DRD2 P14416 2/20 0.49
DRD4 P21917 1/20 0.49
GAA P10253 4/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
RAD52 P43351 1/20 0.45
PAK1 Q13153 1/20 0.44
PKN1 Q16512 1/20 0.44
AXL P30530 1/20 0.43
ADAMTS5 Q9UNA0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6162708 0.86 L3MBTL1 (0.55) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL16387109 0.85 ALDH1A1 (0.62) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL6924885 0.83 ALDH1A1 (0.69) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL19625789 0.81 ALDH1A1 (0.67) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL7923952 0.81 HTR1A (0.58) ALDH1A1HTR3ADRD2DRD4GAA
SCHEMBL21361437 0.81 DRD2 (0.46) ALDH1A1L3MBTL1DRD2DRD4GAA
SCHEMBL30198288 0.80 ALDH1A1 (1.00) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL8714328 0.80 ALDH1A1 (1.00) ALDH1A1L3MBTL1HTR3EHTR3BHTR3A
SCHEMBL30609639 0.80 HTR3A (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL706971 0.80 HTR3A (0.61) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 US disclosed
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 US disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
WO-2021237112-A1 NOTCH INHIBITORS AND USES THEREOF STEMSYNERGY THERAPEUTICS, INC. (US) 2021-11-25 WO disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
US-RE44205-E1 Adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed
US-RE44205-E1 Adenosine A2a receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203003-A1 Notch Inhibitors and Uses Thereof NOTCH1, NOTCH2, NOTCH4 ALDH1A1 2288/4885L3MBTL1 515/4885HTR3E 3305/4885
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G ALDH1A1 4848/4885L3MBTL1 4760/4885HTR3E 3724/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4834/4885L3MBTL1 4748/4885HTR3E 3609/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4817/4885L3MBTL1 4721/4885HTR3E 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.